|
Accueil > Actualité
Amgen: EPS up 13% in Q4
(CercleFinance.com) - Amgen reported adjusted EPS for the last three months of 2024 up 13% to $5.
31, with non-GAAP operating margin down 0.4 points to 46.3% but revenues up 11% to $9.1 billion. Product sales were up 11%, with volume growth of 14%, with ten products recording revenue growth of at least 10%, including Repatha, Blincyto, Tezspire, Evenity and Tavneos. Posting adjusted EPS of $19.84 and revenues of $33.4 billion for the full year 2024, the healthcare group expects respective target ranges between $20 and $21.20 and between $34.3 and $35.7 billion in 2025. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
06/05/2025 07:42
FordBPA plus que divisé par trois au 1er trimestre 06/05/2025 07:25 Vincideux arrivées au comité exécutif 06/05/2025 07:07 Rubiscroissance de 2% du CA trimestriel 05/05/2025 18:33 Crédit Agricolenouveau président du conseil de CA CIB 05/05/2025 18:27 Vincisigne une convention de rachat d'actions 05/05/2025 18:21 Elisconfirme l'ensemble de ses objectifs financiers Tous les articles sociétés |
